Company intelligence / Profile preview

Maxim Pharmaceuticals

Ownership: Private
Development stage: Phase 2

Overview

Maxim Pharmaceuticals has multiple entities with similar names. The US-based entity was acquired by EpiCept Corporation in 2006 and had a lead drug candidate Ceplene for acute myeloid leukemia. The Kenya-based entity is active and focuses on providing pharmaceutical products to East Africa. The India-based entity is also active.

Therapeutic areas: OncologyCardiovascular
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

5 assets

bertilimumab

Phase 2

Indications: Bullous pemphigoid, Ulcerative colitis

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Maxim Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maxim Pharmaceuticals.

Explore the full profile